Ventyx Biosciences to Host R&D Event on January 26, 2023
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a…
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a…
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT),…
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical…
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) — ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and…
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Topline data anticipated in Q2 2023 NEW ORLEANS and LOS ANGELES and LONDON, Jan. 05,…
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022 Procurement Triggered by…
New round of financing led by Vensana Capital will support technology platform expansion and further…
BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech…
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader…
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a…
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics (Minovia), a clinical-stage company focused on…
MANCHESTER, United Kingdom, Jan. 05, 2023 (GLOBE NEWSWIRE) — F2G Ltd. today announced that the…
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has…
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome…
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial…
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that Priya…